Association of asymptomatic bradycardia with incident cardiovascular disease and mortality the multi-ethnic study of atherosclerosis (MESA)

Ajay Dharod, Elsayed Z. Soliman, Farah Dawood, Haiying Chen, Steven Shea, Saman Nazarian, Alain G. Bertoni

Research output: Contribution to journalArticle

Abstract

IMPORTANCE Bradycardia has been associated with lower cardiovascular disease (CVD) risk in selected populations. There is a paucity of information available about heart rate (HR) less than 50 beats per minute (bpm) among middle-Aged or older adults. OBJECTIVE To determine whether asymptomatic bradycardia was associated with a lower cardiovascular risk profile, less subclinical atherosclerosis, and decreased incident CVD and mortality. DESIGN, SETTING, AND PARTICIPANTS This retrospective analysis includes 6733 participants of the Multi-Ethnic Study of Atherosclerosis, which recruited men and women free of clinical cardiovascular disease ages 45 to 84 years from 2000 to 2002 and followed them over 10 years for incident CVD events and mortality. The HR was measured by baseline electrocardiogram. The analysis was performed in June 2014. MAIN OUTCOMES AND MEASURES The association between HR categories with CVD events and all-cause mortality were examined using Cox proportional hazards models adjusted for potential confounders and mediators. RESULTS The 6733 participants had a mean (SD) age of 62 (10.2) years; 47%were male. The mean (SD) HR was 63 (9.5) bpm among the 5831 participants not taking an HR-modifying drug; 5.3%had an HR lower than 50 bpm. Preliminary results revealed significant interaction for HR categories according to use of HR-modifying drugs for mortality (P = .002); thus, all further analyses were stratified. An HR of less than 50 bpm was not associated with incident CVD in either subgroup (participants taking or not taking HR-modifying drugs). Among participants not taking HR-modifying drugs, the fully adjusted mortality risk was not different for an HR less than 50 bpm (hazard ratio, 0.71 [95%CI, 0.41-1.09]; P = .12) and increased among those with an HR greater than 80 bpm (hazard ratio, 1.49 [95%CI, 1.08-2.05]; P = .01) (reference HR, 60-69 bpm). Among the 902 participants taking HR-modifying drugs there was an elevated mortality risk associated with an HR less than 50 bpm (hazard ratio, 2.42 [95%CI, 1.39-4.20]; P = .002) and with an HR greater than 80 bpm (hazard ratio, 3.55 [95% CI, 1.65-7.65]; P = .001) (reference HR, 60-69 bpm). CONCLUSIONS AND RELEVANCE In a contemporary, community-based cohort, bradycardia was generally not associated with incident CVD or mortality except for a potential adverse association between bradycardia among those taking HR-modifying drugs.

Original languageEnglish (US)
Pages (from-to)219-227
Number of pages9
JournalJAMA Internal Medicine
Volume176
Issue number2
DOIs
StatePublished - Feb 1 2016
Externally publishedYes

Fingerprint

Bradycardia
Atherosclerosis
Cardiovascular Diseases
Heart Rate
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Association of asymptomatic bradycardia with incident cardiovascular disease and mortality the multi-ethnic study of atherosclerosis (MESA). / Dharod, Ajay; Soliman, Elsayed Z.; Dawood, Farah; Chen, Haiying; Shea, Steven; Nazarian, Saman; Bertoni, Alain G.

In: JAMA Internal Medicine, Vol. 176, No. 2, 01.02.2016, p. 219-227.

Research output: Contribution to journalArticle

Dharod, Ajay ; Soliman, Elsayed Z. ; Dawood, Farah ; Chen, Haiying ; Shea, Steven ; Nazarian, Saman ; Bertoni, Alain G. / Association of asymptomatic bradycardia with incident cardiovascular disease and mortality the multi-ethnic study of atherosclerosis (MESA). In: JAMA Internal Medicine. 2016 ; Vol. 176, No. 2. pp. 219-227.
@article{a7b350ed8ffa42d6a7c7453c683e54e2,
title = "Association of asymptomatic bradycardia with incident cardiovascular disease and mortality the multi-ethnic study of atherosclerosis (MESA)",
abstract = "IMPORTANCE Bradycardia has been associated with lower cardiovascular disease (CVD) risk in selected populations. There is a paucity of information available about heart rate (HR) less than 50 beats per minute (bpm) among middle-Aged or older adults. OBJECTIVE To determine whether asymptomatic bradycardia was associated with a lower cardiovascular risk profile, less subclinical atherosclerosis, and decreased incident CVD and mortality. DESIGN, SETTING, AND PARTICIPANTS This retrospective analysis includes 6733 participants of the Multi-Ethnic Study of Atherosclerosis, which recruited men and women free of clinical cardiovascular disease ages 45 to 84 years from 2000 to 2002 and followed them over 10 years for incident CVD events and mortality. The HR was measured by baseline electrocardiogram. The analysis was performed in June 2014. MAIN OUTCOMES AND MEASURES The association between HR categories with CVD events and all-cause mortality were examined using Cox proportional hazards models adjusted for potential confounders and mediators. RESULTS The 6733 participants had a mean (SD) age of 62 (10.2) years; 47{\%}were male. The mean (SD) HR was 63 (9.5) bpm among the 5831 participants not taking an HR-modifying drug; 5.3{\%}had an HR lower than 50 bpm. Preliminary results revealed significant interaction for HR categories according to use of HR-modifying drugs for mortality (P = .002); thus, all further analyses were stratified. An HR of less than 50 bpm was not associated with incident CVD in either subgroup (participants taking or not taking HR-modifying drugs). Among participants not taking HR-modifying drugs, the fully adjusted mortality risk was not different for an HR less than 50 bpm (hazard ratio, 0.71 [95{\%}CI, 0.41-1.09]; P = .12) and increased among those with an HR greater than 80 bpm (hazard ratio, 1.49 [95{\%}CI, 1.08-2.05]; P = .01) (reference HR, 60-69 bpm). Among the 902 participants taking HR-modifying drugs there was an elevated mortality risk associated with an HR less than 50 bpm (hazard ratio, 2.42 [95{\%}CI, 1.39-4.20]; P = .002) and with an HR greater than 80 bpm (hazard ratio, 3.55 [95{\%} CI, 1.65-7.65]; P = .001) (reference HR, 60-69 bpm). CONCLUSIONS AND RELEVANCE In a contemporary, community-based cohort, bradycardia was generally not associated with incident CVD or mortality except for a potential adverse association between bradycardia among those taking HR-modifying drugs.",
author = "Ajay Dharod and Soliman, {Elsayed Z.} and Farah Dawood and Haiying Chen and Steven Shea and Saman Nazarian and Bertoni, {Alain G.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1001/jamainternmed.2015.7655",
language = "English (US)",
volume = "176",
pages = "219--227",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Association of asymptomatic bradycardia with incident cardiovascular disease and mortality the multi-ethnic study of atherosclerosis (MESA)

AU - Dharod, Ajay

AU - Soliman, Elsayed Z.

AU - Dawood, Farah

AU - Chen, Haiying

AU - Shea, Steven

AU - Nazarian, Saman

AU - Bertoni, Alain G.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - IMPORTANCE Bradycardia has been associated with lower cardiovascular disease (CVD) risk in selected populations. There is a paucity of information available about heart rate (HR) less than 50 beats per minute (bpm) among middle-Aged or older adults. OBJECTIVE To determine whether asymptomatic bradycardia was associated with a lower cardiovascular risk profile, less subclinical atherosclerosis, and decreased incident CVD and mortality. DESIGN, SETTING, AND PARTICIPANTS This retrospective analysis includes 6733 participants of the Multi-Ethnic Study of Atherosclerosis, which recruited men and women free of clinical cardiovascular disease ages 45 to 84 years from 2000 to 2002 and followed them over 10 years for incident CVD events and mortality. The HR was measured by baseline electrocardiogram. The analysis was performed in June 2014. MAIN OUTCOMES AND MEASURES The association between HR categories with CVD events and all-cause mortality were examined using Cox proportional hazards models adjusted for potential confounders and mediators. RESULTS The 6733 participants had a mean (SD) age of 62 (10.2) years; 47%were male. The mean (SD) HR was 63 (9.5) bpm among the 5831 participants not taking an HR-modifying drug; 5.3%had an HR lower than 50 bpm. Preliminary results revealed significant interaction for HR categories according to use of HR-modifying drugs for mortality (P = .002); thus, all further analyses were stratified. An HR of less than 50 bpm was not associated with incident CVD in either subgroup (participants taking or not taking HR-modifying drugs). Among participants not taking HR-modifying drugs, the fully adjusted mortality risk was not different for an HR less than 50 bpm (hazard ratio, 0.71 [95%CI, 0.41-1.09]; P = .12) and increased among those with an HR greater than 80 bpm (hazard ratio, 1.49 [95%CI, 1.08-2.05]; P = .01) (reference HR, 60-69 bpm). Among the 902 participants taking HR-modifying drugs there was an elevated mortality risk associated with an HR less than 50 bpm (hazard ratio, 2.42 [95%CI, 1.39-4.20]; P = .002) and with an HR greater than 80 bpm (hazard ratio, 3.55 [95% CI, 1.65-7.65]; P = .001) (reference HR, 60-69 bpm). CONCLUSIONS AND RELEVANCE In a contemporary, community-based cohort, bradycardia was generally not associated with incident CVD or mortality except for a potential adverse association between bradycardia among those taking HR-modifying drugs.

AB - IMPORTANCE Bradycardia has been associated with lower cardiovascular disease (CVD) risk in selected populations. There is a paucity of information available about heart rate (HR) less than 50 beats per minute (bpm) among middle-Aged or older adults. OBJECTIVE To determine whether asymptomatic bradycardia was associated with a lower cardiovascular risk profile, less subclinical atherosclerosis, and decreased incident CVD and mortality. DESIGN, SETTING, AND PARTICIPANTS This retrospective analysis includes 6733 participants of the Multi-Ethnic Study of Atherosclerosis, which recruited men and women free of clinical cardiovascular disease ages 45 to 84 years from 2000 to 2002 and followed them over 10 years for incident CVD events and mortality. The HR was measured by baseline electrocardiogram. The analysis was performed in June 2014. MAIN OUTCOMES AND MEASURES The association between HR categories with CVD events and all-cause mortality were examined using Cox proportional hazards models adjusted for potential confounders and mediators. RESULTS The 6733 participants had a mean (SD) age of 62 (10.2) years; 47%were male. The mean (SD) HR was 63 (9.5) bpm among the 5831 participants not taking an HR-modifying drug; 5.3%had an HR lower than 50 bpm. Preliminary results revealed significant interaction for HR categories according to use of HR-modifying drugs for mortality (P = .002); thus, all further analyses were stratified. An HR of less than 50 bpm was not associated with incident CVD in either subgroup (participants taking or not taking HR-modifying drugs). Among participants not taking HR-modifying drugs, the fully adjusted mortality risk was not different for an HR less than 50 bpm (hazard ratio, 0.71 [95%CI, 0.41-1.09]; P = .12) and increased among those with an HR greater than 80 bpm (hazard ratio, 1.49 [95%CI, 1.08-2.05]; P = .01) (reference HR, 60-69 bpm). Among the 902 participants taking HR-modifying drugs there was an elevated mortality risk associated with an HR less than 50 bpm (hazard ratio, 2.42 [95%CI, 1.39-4.20]; P = .002) and with an HR greater than 80 bpm (hazard ratio, 3.55 [95% CI, 1.65-7.65]; P = .001) (reference HR, 60-69 bpm). CONCLUSIONS AND RELEVANCE In a contemporary, community-based cohort, bradycardia was generally not associated with incident CVD or mortality except for a potential adverse association between bradycardia among those taking HR-modifying drugs.

UR - http://www.scopus.com/inward/record.url?scp=84957946869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957946869&partnerID=8YFLogxK

U2 - 10.1001/jamainternmed.2015.7655

DO - 10.1001/jamainternmed.2015.7655

M3 - Article

VL - 176

SP - 219

EP - 227

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 2

ER -